Expected outcomes
What should improve.
- 0.2-0.6% HbA1c reduction over 4-6 months for adherent members
- 30-50% reduction in HOMA-IR for the same window
- ApoB and TG/HDL trending into preventive ranges

Protocol
Pre-diabetes, MetSyn, and HOMA-IR > 2.0 - reversed before any GLP-1 conversation.
Medically reviewed byDr. Lena Okafor, MD
Medical Director - updated April 2026How we review
Best fit
We screen eligibility before any prescription enters the conversation. Decline is treated as an outcome, not a failure.
Contraindications
These are hard stops. We route into a different protocol or refer out, rather than working around a contraindication.
Execution
Each phase has explicit entry criteria, actions, and exit conditions. The plan moves on data and tolerance, not a calendar.
Phase 01
Weeks 0-2
Quantify insulin resistance, identify the dominant driver, and set the lifestyle floor before changing anything else.
Phase 02
Weeks 3-12
Stack the highest-evidence lifestyle levers - protein, fiber, training volume, sleep regularity - while measuring adherence weekly.
Phase 03
Weeks 13-24
Recheck the markers and decide whether to extend, layer berberine or metformin, or escalate to a regulated GLP-1 pathway.
Stack components
Prescription
Provider-selected and state-dependent.
Labs
Coaching
Expected outcomes
Risk picture
Monitoring cadence
Labs and availability
Common questions
Evidence
Trials, regulatory guidance, and peer-reviewed evidence the protocol is anchored against.
Keep reading
Provider-reviewed care vs DIY supplementation: when each makes sense
Every week, someone self-prescribes GLP-1 from a sketchy site, orders SARMs off Reddit, or pulls ferritin off their chart and changes nothing. Here's the real...
ReadFasting insulin and HOMA-IR: the metabolic signal that precedes A1c by years
By the time HbA1c crosses 5.7% and your PCP calls you "pre-diabetic," your fasting insulin has likely been elevated for 5-10 years. A normal HbA1c is the last...
ReadInsulin resistance early markers: what shows up before A1c moves
A1c can look normal while insulin resistance is already progressing. Early markers such as fasting insulin, triglyceride patterns, waist trend, and post-meal...
ReadALUKARD vs Function Health: treatment execution versus lab breadth
Function Health is built around broad laboratory visibility. ALUKARD is built around turning biomarker signal into protocol execution. This comparison...
ReadLongevity
ApoB, hs-CRP, HbA1c, fasting insulin, thyroid. Re-measured every quarter. Sequenced by a provider. Never sold as a stack.
ReadWeight Management
Most weight struggles have a metabolic driver the scale never shows. We find it, treat it, and only talk medication when the data says to.
ReadBuild your plan
Take the assessment and we’ll route you into labs, a foundational stack, coaching, or provider review based on what you answer.
